BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38279601)

  • 21. Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.
    van Not OJ; de Meza MM; van den Eertwegh AJM; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; van Breeschoten J; de Groot JB; Hospers GAP; Ismail RK; Kapiteijn E; Piersma D; van Rijn RS; Stevense-den Boer MAM; van der Veldt AAM; Vreugdenhil G; Bonenkamp HJ; Boers-Sonderen MJ; Blokx WAM; Wouters MWJM; Suijkerbuijk KPM
    Eur J Cancer; 2022 May; 167():70-80. PubMed ID: 35395553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
    Afzal MZ; Mercado RR; Shirai K
    J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
    Afzal MZ; Shirai K
    Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
    Kopecky J; Kubecek O; Priester P; Vosmikova H; Cermakova E; Kyllarova A
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):393-404. PubMed ID: 34446937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
    Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
    Betof AS; Nipp RD; Giobbie-Hurder A; Johnpulle RAN; Rubin K; Rubinstein SM; Flaherty KT; Lawrence DP; Johnson DB; Sullivan RJ
    Oncologist; 2017 Aug; 22(8):963-971. PubMed ID: 28476944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
    Li L; Zhang Z; Hu Y
    Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
    Nakamura Y; Namikawa K; Yoshino K; Yoshikawa S; Uchi H; Goto K; Nakamura Y; Fukushima S; Kiniwa Y; Takenouchi T; Uhara H; Kawai T; Hatta N; Funakoshi T; Teramoto Y; Otsuka A; Doi H; Ogata D; Matsushita S; Isei T; Hayashi T; Shibayama Y; Yamazaki N
    Ann Oncol; 2020 Sep; 31(9):1198-1206. PubMed ID: 32522691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 35. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
    Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
    Cho KK; Cust AE; Foo YM; Long GV; Menzies AM; Eslick GD
    Melanoma Res; 2021 Oct; 31(5):482-486. PubMed ID: 34433196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
    Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
    Front Immunol; 2021; 12():672521. PubMed ID: 34177913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series.
    Wen X; Ding Y; Li J; Zhao J; Peng R; Li D; Zhu B; Wang Y; Zhang X; Zhang X
    Cancer Immunol Immunother; 2017 Sep; 66(9):1153-1162. PubMed ID: 28444424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.